Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
about
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.The proteasome and proteasome inhibitors in multiple myeloma.Triplet vs. doublet drug regimens for managing multiple myeloma.An overview of the role of carfilzomib in the treatment of multiple myeloma.
P2860
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Carfilzomib, lenalidomide, and ...... from the phase 3 ASPIRE study
@ast
Carfilzomib, lenalidomide, and ...... from the phase 3 ASPIRE study
@en
type
label
Carfilzomib, lenalidomide, and ...... from the phase 3 ASPIRE study
@ast
Carfilzomib, lenalidomide, and ...... from the phase 3 ASPIRE study
@en
prefLabel
Carfilzomib, lenalidomide, and ...... from the phase 3 ASPIRE study
@ast
Carfilzomib, lenalidomide, and ...... from the phase 3 ASPIRE study
@en
P2093
P2860
P50
P356
P1476
Carfilzomib, lenalidomide, and ...... from the phase 3 ASPIRE study
@en
P2093
A Keith Stewart
Aleksandr Suvorov
Andrzej Jakubowiak
David Siegel
Georgi G Mihaylov
Laura Rosiñol
Mihaela Obreja
Sanjay Aggarwal
Vesselina Goranova-Marinova
P2860
P304
P356
10.1111/BJH.14549
P407
P50
P577
2017-02-17T00:00:00Z